Zerbor/iStock via Getty Images
- Despite releasing Q1 2024 results that beat on both lines, Dexcom (NASDAQ:DXCM) is down ~7% in after-hours trading Thursday.
- The continuous glucose monitor maker’s updated 2024 revenue outlook range is now $4.20B-$4.35B. Consensus is $4.33B.
- The company did not provide EPS guidance. However, the non-GAAP EPS consensus for the year is $1.75.
- On a non-GAAP basis, net income in the quarter was $128.2M compared to $68.5M in the year-ago period. Non-GAAP diluted net income per share of $0.32 compared to $0.17 in Q1 2023.
